Drugs / Tylenol #3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04044820 | Mar 2019 → Dec 2026 expected | substance-related disorder | University Health Network, Toronto | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03469310 Comparator | Mar 2018 → Dec 2019 | goiter, parathyroid gland adenoma, parathyroid hyperplasia, thyroid cancer | Minerva A Romero Arenas | Completed | No outcome recorded |
| Phase 4 | NCT02095665 Background | Jan 2014 → Mar 2018 | nephrolithiasis | Nova Scotia Health Authority | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tylenol #3 | “Tylenol #3 1-2 tablets PO q4h PRN” NCT04044820 ↗ |
| Modality | Other / unclassified | “Narcotic analegesic only” NCT02095665 ↗ |
| Route | Oral | “Tylenol #3 Oral Tablet” NCT03469310 ↗ |